Kornimate/medical-research-clean huggingface dataset:
surgical hand washing and sterile dressing training with virtual reality glasses

Conditions: Virtual Reality

Summary: abstract this study is a comparison of the impact of virtual reality on surgical handwashing and sterile dressing knowledge, skills, satisfaction, and confidence in nursing students enrolled in surgical nursing, as opposed to conventional teaching methods. keywords: virtual reality, surgical nursing education, surgical handwashing and sterile dressing skills, scenario-based education, three-dimensional video education.

this research is a randomized controlled experimental study aiming to investigate the impact of scenario-based three-dimensional video education using virtual reality goggles on surgical handwashing and sterile dressing skills. volunteer nursing students, forming the research sample, were divided into three groups using a simple random sampling method. the first group was provided with an 11-minute vr experience using virtual reality goggles, repeated three times. the second group received theoretical training methods, with a one-time 30-minute session and a demonstration, followed by free study time. the third group received training three times with an 11-minute video. three weeks later, the students' skills were assessed using a validated skills assessment form. their confidence and satisfaction levels were evaluated through a questionnaire.

Eligibility criteria:
inclusion criteria: to be 18 years and older, being an active student of the nursing department, being enrolled in the surgical nursing diseases course for the first time, not having claustrophobia, not having head or neck disorders that would prevent wearing virtual reality goggles. exclusion criteria: being a graduate of a health vocational high school, being a graduate of a pre-license health services vocational college, having attended any webinar, congress, or meeting related to surgical hand washing and sterile dressing, having professional working experience in the nursing/healthcare field.

Keywords: virtual reality surgical nursing education surgical handwashing and sterile dressing skills three-dimensional video education scenario-based training
pogo® automatic blood glucose monitoring system clinical study

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to determine if the pogo® system delivers accurate blood glucose readings in the hands of the lay user and assess the pogo® system accuracy when used by trained health care professionals.

subjects will review labeling materials and self-test using the pogo® system. an hcp-assisted test also will be performed; both tests will be compared to a fingerstick capillary sample run on a ysi reference glucose analyzer. subjects will complete questionnaires on labeling comprehension and pogo® usability.

Eligibility criteria:
inclusion criteria: * be diagnosed with diabetes * be 18 years of age or older * be able to read, write, and understand english fluently * be able and willing to give written informed consent and have provided signed, written consent exclusion criteria: * any condition which in the opinion of the investigator may place the subject or site personnel at excessive risk * a physical condition or limitation that prevents the subject from reading the labeling and using a bgms on their own * previous experience with the pogo® bgms * formal experience with clinical (medical) laboratory equipment or formal training in a relevant medical field
esg vs lsg: short-term nutritional outcomes

Conditions: Endoscopic Sleeve Gastroplasty; Laparoscopic Sleeve Gastrectomy; Obesity

Summary: to assess endoscopic sleeve gastroplasty in comparison to laparoscopic sleeve gastrectomy before and 3 months after the procedure in terms of multiple nutrition-related factors, quality of life, weight and other related parameters.

this will be a short-term prospective cohort study, single-center study (newyou clinical center - riyadh). a total of 15 endoscopic sleeve gastroplasty patients will be matched with 15 laparoscopic sleeve gastrectomy patients by age, gender and bmi. total sample size is 30 patients. sample size was selected based on literature, considering the sample will be surgical patients and based on booked patients in the clinic. a multidisciplinary team will provide post-procedure care (including post-surgery diet stages protocol given by the center).

Eligibility criteria:
inclusion criteria: * adult (≥ 18 years old) * willingness and ability to participate * males and females * non-pregnant exclusion criteria: * children (\<18 years old) * pregnant
safety and efficacy of therapeutic anticoagulation with tinzaparin during pregnancy via weight-based dosing

Conditions: Venous Thromboembolism

Summary: the purpose of this study is to evaluate the safety and efficacy of therapeutic anticoagulation with tinzaparin during pregnancy via weight-based dosing.

physicians in the calgary health region are using tinzaparin (predominantly) and other low molecular weight heparins (lmwhs) for the treatment venous thromboembolism (vte) in pregnancy. the most recent anticoagulation guidelines from american college of chest physicians (accp) suggest that heparin levels (anti-factor-xa activity levels) may be done periodically through pregnancy to determine the need to adjust the dose of lmwh as pregnancy progresses. this monitoring is widely practiced. there is no clear consensus in the literature, however, with some experts suggesting that initial and subsequent dosing may be done based on weight alone (as is done in the non-pregnant population). given the multiple physiologic changes which occur to drug metabolism during pregnancy, this bears further evaluation. to date, there is very limited data on weight-adjusted dosing of lmwh in pregnancy. this study is therefore designed to determine if dosing of tinzaparin during pregnancy based on weight, with periodic weight-based adjustments, will result in adequate therapeutic anticoagulation.

Eligibility criteria:
inclusion criteria: * singleton pregnancies in women over the age of 18 requiring anticoagulation for acute vte (dvt/pe), or high-risk prophylaxis at a tinzaparin dose of 175 iu/kg. * high-risk patients include those with multiple (two or more) episodes of vte and/or women receiving long-term anticoagulants (e.g. single event with known thrombophilia; aplas and history of venous thrombosis) exclusion criteria: * multiple gestation\\ * prosthetic valves * active bleeding or other contraindication to anticoagulation therapy * allergy to heparin, bisulfites, or fish, history of hit (heparin induced thrombocytopenia), severe hypertension (diastolic \>130) * severe hepatic or renal failure * patients over 100kg.

Keywords: anticoagulation pregnancy
cold plasma for wound treatment, safety study

Conditions: Intact Skin; Contaminant Given to Patient

Summary: in this study the application of cold atmospheric plasma (cap) will be tested on intact skin of volunteers. to test safety, several skin parameters will be monitored, the antimicrobial effect will be investigated as well. the investigators expect this treatment to have a good antimicrobial effect with acceptable, transient skin sensations.

control of infection and bacterial colonisation constitutes a continuing challenge in patients with burns. prevention of microbial contamination and infection is vital for burn wound care as bacterial presence can result in excessive inflammatory reactions, delayed re-epithelialisation, impaired matrix remodelling and bacteraemia. a novel method to decrease the likelihood of infection and to help cure wounds is cold atmospheric plasma (cap). cap has been shown in vitro to kill a wide range of pathogenic bacteria. this safety study aims to demonstrate the safety, efficacy and efficiency of cap for burn wound treatment. intact skin of volunteers will be cap treated. local skin reaction (blister formation, pain, itching), erythema, local skin temperature, trans epidermal water loss (tewl) and reduction of the bacterial load wil be monitored.

Eligibility criteria:
inclusion criteria: * able and willing to comply with the research protocol * no language barrier exclusion criteria: * atopic dermatitis or other skin disease * implanted electrical medical devices such cardiac pacemakers * pregnant or lactating women * patients with infected wounds. * life-threatening cardiac conductivity abnormality * active malignancy * women of childbearing age not using contraceptive measures

Keywords: cold atmospheric plasma pain bacteria skin parameters
botox for non-surgical lateral release in patellofemoral pain

Conditions: Patellofemoral Pain Syndrome

Summary: the purpose of this study is to determine whether the use of botulinum toxin a injected into the lateral thigh muscle improves knee function and reduces knee pain secondary to patellofemoral syndrome. the study hypothesis is that botulinum toxin + specific exercises will be superior to specific exercises alone in improving knee function and reducing knee pain in individuals with patellofemoral syndrome.

patellofemoral pain syndrome is a leading cause of knee pain in persons under 45 and is particularly common in women. the prevailing theory for the etiology of patellofemoral pain is an imbalance in force or timing of the pull of the knee extensor muscles on the patella resulting in improper tracking of the patella in the femoral grove. specifically, the vastus medialis is thought to be ineffective in overcoming the lateral pull of the vastus lateralis. when exercises designed to focus on improving strength and timing of activation of the vastus medialis fail, surgical release of part of the attachment of the vastus lateralis to the patella is considered. botulinum toxin temporarily blocks acetylcholine release from motor neurons and is used clinically to produce muscle relaxation. subjects with patellofemoral syndrome will be recruited into the study. half of the subjects will be given a placebo injection while the other half will be given an injection of botox (botulinum toxin a, allergen) into the vastus lateralis muscle. group assignment will be randomized and a double blind protocol used. prior to injection, the subject will record their level of knee pain, fill out several knee function questionnaires, and have the strength and endurance of their knee extensor muscles tested. all subjects will be given an exercise program designed to target strengthening of the medial thigh muscles as well as stretching of lateral structures. at 4, 6 and 12 weeks knee pain and knee function will again be assessed.

Eligibility criteria:
inclusion criteria: * retropatellar knee pain * pain with two of: prolonged sitting, climbing stairs, squatting, running, kneeling, hopping, jumping * pain with patellar palpation * symptoms minimum 1 month * visual analog scale for pain (vas) usual pain 4 of 10 on vas \[0-10 scale, anchors 0 = no pain, 10 = worst pain imaginable\] exclusion criteria: * history knee surgery * history patellar dislocation * clinical evidence of meniscal lesion, ligamentous instability, traction apophysitis around the patellofemoral complex, patellar tendon pathology, chondral damage, osteoarthrosis, spinal referred pain

Keywords: botulinum toxin type a patellofemoral pain syndrome knee injuries exercise therapy
goal achievement after utilizing an anti-pcsk9 antibody in statin intolerant subjects

Conditions: Hyperlipidemia

Summary: the primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (amg 145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (ldl-c) in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 to ≤ 75 years of age * on a statin or a low dose statin with stable dose for at least 4 weeks * lipid lowering therapy has been stable prior to enrollment * fasting triglycerides must be \< 400 mg/dl. * subject not at ldl-c goal exclusion criteria: * new york heart association (nyha) iii or iv heart failure or known left ventricular ejection fraction \< 30% * uncontrolled cardiac arrhythmia * myocardial infarction, unstable angina, percutaneous coronary intervention (pci), coronary artery bypass graft (cabg) or stroke within 3 months prior to randomization * type 1 diabetes or newly diagnosed type 2 diabetes (hba1c \> 8.5%) * uncontrolled hypertension

Keywords: proprotein convertase subtilisin/kexin type 9 (pcsk9) cholesterol high cholesterol raised cholesterol elevated cholesterol statin intolerant hypercholesterolemia
safety and efficacy of wide awake local anesthesia no tourniquet technique (walant) in ankle removal of implant surgery

Conditions: Safety Issues; Post Operative Pain; Local Anesthetic Complication

Summary: safety and efficacy of wide awake local anesthesia no torniquet technique (walant) in ankle surgery. studying risks and benefits from walant compared to general anesthesia . walant expected to decrease in intraoperative/post operative pain at the surgical site and decrease hospital time .


Eligibility criteria:
inclusion criteria: * age: \>18 * previous orif for: * unimalleolar fractures * bimalleolar fractures * trimalleolar fractures exclusion criteria: * allergy to local anesthesia * psychiatric diagnosis including: affect disorders, uncooperative * severe cardiovascular disease
a prospective registry to assess the effectiveness and local tolerability of intravesical valrubicin in subjects with non-muscle invasive bladder cancer (nmibc)

Conditions: Bladder Cancer; CIS

Summary: the purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (nmibc) in a cohort of subjects treated under routine practice conditions.


Eligibility criteria:
inclusion criteria: * males and females 18 years of age and older * diagnosed with nmibc * prescribed intravesical valrubicin to treat nmibc * understood and signed informed consent to participate exclusion criteria: * none

Keywords: non-muscle invasive bladder cancer cis bcg refractory
deep neural networks on the accuracy of skin disease diagnosis in non-dermatologists

Conditions: Skin Diseases

Summary: background: deep neural networks (dnn) has been applied to many kinds of skin diseases in experimental settings. objective: the objective of this study is to confirm the augmentation of deep neural networks for the diagnosis of skin diseases in non-dermatologist physicians in a real-world setting. methods: a total of 40 non-dermatologist physicians in a single tertiary care hospital will be enrolled. they will be randomized to a dnn group and control group. by comparing two groups, the investigators will estimate the effect of using deep neural networks on the diagnosis of skin disease in terms of accuracy.

in the dnn group and control group, these steps are the same process. 1. routine exam and capture photographs of skin lesions for all eligible consecutive series patient. 2. make a clinical diagnosis (before-dx) 3. make a clinical diagnosis (after-dx) 4. consult to dermatologist in the dnn group, after making the before-dx, physicians use deep neural networks and make an after-dx considering the results of the deep neural networks (model dermatology, build 2020). in the control group, after making the before-dx, physicians make an after-dx after reviewing the pictures of skin lesions once more. ground truth will be based on the biopsy if available, or the consensus diagnosis of the dermatologists. the investigators will compare the accuracy between the dnn group and control group after 6 consecutive months study.

Eligibility criteria:
inclusion criteria: * non-dermatologist physician (residents) who agree to participate in this study exclusion criteria: * dermatology residents * non-dermatology residents who use other deep neural networks for skin lesion diagnosis

Keywords: skin diseases deep neural networks
study to evaluate and compare the pk profiles of abaloparatide-sc and abaloparatide-smts in a cohort of healthy men and healthy women.

Conditions: Healthy Volunteers

Summary: a study to evaluate and compare the pk profiles of abaloparatide-sc 80 μg and abaloparatide-smts 300 μg in a cohort of healthy men and to make a similar evaluation in a cohort of healthy women

this study aims to evaluate and compare the pharmacokinetic (pk) profiles of abaloparatide-sc 80 μg injected subcutaneously into the periumbilical region of the abdomen, and abaloparatide-smts 300 μg applied to the thigh for 5 minutes in a cohort of healthy men and to make a similar evaluation in a cohort of healthy women.

Eligibility criteria:
inclusion criteria * male and female subjects aged 40 to 65 years old, inclusive, at screening; * good general health as determined by medical history and physical exam (including vital signs, and has a body mass index between 18 and 32 kg/m\^2; * laboratory test results within the normal range * serum 25-hydroxyvitamin d values must be \> 20 ng/ml. exclusion criteria: * presence or history of any disorder that may prevent the successful completion of the study; * diagnosed with osteoporosis, paget's disease, or other metabolic bone diseases (eg, vitamin d deficiency or osteomalacia), or had a non-traumatic fracture within 1 year prior to the initial screening; * history of any cancer within the past 5 years other than squamous or basal cell carcinoma; * history of allergy to abaloparatide or drugs in a similar pharmacological class;.

Keywords: osteoporosis transdermal delivery solid microstructured transdermal system abaloparatide tymlos® abaloparatide-sc abaloparatide-smts pk
antidepressant incomplete response depression

Conditions: Major Depressive Disorder

Summary: observational, non-interventional, longitudinal, prospective,multicenter, open label (no treatment is involved). 3 assessment will be carried out . the 1st one will be on baseline, the 2sd one after a significant change in pharmacological treatment and 3rd one after a second significant change in pharmacological treatment. if there isn´t any significant change in therapeutic plan a control assessment will be carry out in week 10th and 24th. a significant treatment change is defined as a change in ssri/snri, to add another ssri/snri or a augmentation treatment added to ssri/snri. the primary objective is to describe therapeutical strategies (antidepressant change, association with another antidepressant or association with another treatment) in the management of patients with mdd with incomplete response or intolerance to an antidepressant after a first or a second failure; and when the psychiatrist decide a change of strategy. secondary objectives include: 1 - to describe the clinic profile of depressive patients with incomplete response or intolerance to an antidepressant after a first or a second failure; 2- to describe the profile of patients based on therapeutic strategies used and number of therapeutic strategies; 4- evaluate the use of health resource due to lack of fast onset of action, and social cost (productivity, care givers...); 5 - to associate clinical variable with therapeutic action by psychiatrist.


Eligibility criteria:
inclusion criteria: * provision of written inform consent * diagnosed of major depressive disorder based on dsm-iv-tr * outpatient who has a change in pharmacological therapeutic plan after an incomplete response or intolerance to a treatment with an adequate dosage of an antidepressant (ssri/nsri) 5 * able to understand and to comply with requirements of the study exclusion criteria: * mental retardation * to have been recruited in a clinical trial in the last 4 weeks or to have planned the inclusion in a clinical trial during the follow-up of this study * mdd secondary to substance abuse or somatic illness * actual depressive episode with \ 12 months of length * current treatment with \>1 ssri/srni or previous treatment with \>1 ssri/srni, augmentation treatment with ssri/srni, intravenous antidepressant treatment, tms, ect or mao

Keywords: depression major depressive disorder ssri resistant depression strategies in depression
exploratory assessment of the quantra® system in adult ecmo patients

Conditions: Blood Loss; Thrombosis; Extracorporeal Circulation; Complications

Summary: this is a prospective, observational exploratory study of the performance of the quantra system in adult patients that are undergoing an arterio-venous (av), veno-venous (vv) ecmo or extra-corporeal life support (ecls) procedure.

patients 18 years or older that are undergoing an arterio-venous (av), veno-venous (vv) ecmo or extra-corporeal life support (ecls) procedure will be enrolled in this prospective, observational exploratory study. from each enrolled subject, blood samples will be collected at multiple time points for analysis on the quantra qplus or qstat cartridge in parallel with other assessments performed as standard of care.

Eligibility criteria:
inclusion criteria: * subject is \> 18 years. * subject is scheduled to undergo either va or vv ecmo procedure or has been placed on va or vv ecmo within 24 hours. * subject or subject's legally authorized representative (lar) is willing to provide informed consent, either prospectively or by deferred consent. exclusion criteria: * subject is younger than 18 years of age. * subject is pregnant. * subject is incarcerated at the time of the study. * subject, or subject's legally authorized representative is unable or unwilling to provide informed consent. * subject is affected by a condition that, in the opinion of the treatment team, may pose additional risks.

Keywords: quantra ecmo qplus viscoelastic testing coagulation